CORC

在结果中检索

CORC

浏览/检索结果: 共53条，第1-10条 帮助

限定条件                
已选(0)清除 条数/页：   排序方式：
Clinical relevance and significance of programmed death-ligand I expression, tumor-infiltrating lymphocytes, and p16 status in sinonasal squamous cell carcinoma 期刊论文
CANCER MANAGEMENT AND RESEARCH, 2019, 卷号: 11
作者:  Wang, Shuyi;  Yan, Li;  Quan, Huatao;  Wang, Shengzi
收藏  |  浏览/下载：45/0  |  提交时间：2019/12/05
MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1 期刊论文
GASTROENTEROLOGY, 2019, 卷号: 156, 期号: 6
作者:  Li, Hui;  Li, Chia-Wei;  Li, Xiaoqiang;  Din, Qingqing;  Guo, Lei
收藏  |  浏览/下载：27/0  |  提交时间：2019/12/05
Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway 期刊论文
CANCER LETTERS, 2019, 卷号: 460
作者:  Pu, Ning;  Gao, Shanshan;  Yin, Hanlin;  Li, Jian-ang;  Wu, Wenchuan
收藏  |  浏览/下载：41/0  |  提交时间：2019/12/05
CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions 期刊论文
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 卷号: 68, 期号: 3
作者:  Zi, Zhenguo;  Jin, Yanling;  Li, Gaoxin;  Shao, Kang;  Cai, Qiliang
收藏  |  浏览/下载：19/0  |  提交时间：2019/12/05
Characteristics of enterovirus 71-induced cell death and genome scanning to identify viral genes involved in virus-induced cell apoptosis 期刊论文
VIRUS RESEARCH, 2019, 卷号: 265
作者:  Bai, Jinjin;  Chen, Xixi;  Liu, Qingqing;  Zhou, Xin;  Long, Jian-Er
收藏  |  浏览/下载：18/0  |  提交时间：2019/12/05
Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors 期刊论文
THERANOSTICS, 2019, 卷号: 9, 期号: 16
作者:  Lu, Jia-Cheng;  Zeng, Hai-Ying;  Sun, Qi-Man;  Meng, Qing-Nan;  Huang, Xiao-Yong
收藏  |  浏览/下载：35/0  |  提交时间：2019/12/05
Advanced non-small cell lung cancer patients with low tumor mutation burden might derive benefit from anti-programmed cell death (PD)-1 and anti-programmed deathligand 1 (PD-L1) blockade 会议论文
作者:  Nie, W.;  Xu, M-D.;  Gan, L.;  Zhang, Y.;  Han, B-H.
收藏  |  浏览/下载：9/0  |  提交时间：2019/12/05
Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma - Trial in progress 会议论文
作者:  Ren, Z.;  Assenat, E.;  Cubillo, A.;  Pluntke, S.;  Rimassa, L.
收藏  |  浏览/下载：11/0  |  提交时间：2019/12/05
Programmed Death-Ligand 1 status evaluation using Fluorescence in situ hybridization, RNAscope and Immunohistochemistry in Diffuse Large B-cell Lymphoma 会议论文
作者:  Sun, Chenbo;  Jia, Yijun;  Tian, Tian;  Zhou, Xiaoyan
收藏  |  浏览/下载：6/0  |  提交时间：2019/12/05
The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis 期刊论文
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2018, 卷号: 17, 期号: 2
作者:  Gao, He-Li;  Liu, Liang;  Qi, Zi-Hao;  Xu, Hua-Xiang;  Wang, Wen-Quan
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace